|
|
| Nomenclature |
|
Symbol:
|
Tg(tetO-BCR/ABL1)2Dgt
|
|
Name:
|
transgene insertion 2, Daniel G Tenen
|
|
MGI ID: |
MGI:2387680 |
|
Synonyms: |
BCR-ABL, BCR-ABL1, BCR-ABL stg, p210-BCR-ABL, p210 BCR-ABL1 transponder, Tg(BCR/ABL1)2Dgt, Tg(BCR/ABL1)3Dgt, TRE-BCR-ABL, TRE-BCR/ABL, TRE-P10 BCR/ABL, TRE-p210-BCR-ABL |
|
Transgene:
|
Tg(tetO-BCR/ABL1)2Dgt
Location:
unknown
|
|
Transgene
origin |
|
Transgene
description |
|
Transgene
Type: | |
Transgenic (random, expressed) |
|
Mutation: | |
Insertion |
| |
|
Mutation details: The transgene contains a cDNA encoding the human p210 BCR-ABL1 fusion protein (B3A2 form; J:86227) under transcriptional control of the tetracycline-responsive element (tetO; also called TRE) fused to a minimal cytomegalovirus (CMV) promoter. In doubly transgenic mice expressing a tetracycline transactivator or reverse transactivator protein under control of a ubiquitous or tissue-specific promoter, expression of the BCL-ABL1 fusion gene can be controlled temporally by withdrawal or administration of a tetracycline analog. (J:72377)
|
|
Phenotypes
|
View phenotypes for all genotypes (concatenated display).
|
|
Disease models
|
|
| Find Mice (IMSR) |
Mouse strains and cell lines available from the
International Mouse Strain Resource
(IMSR)
|
|
Notes |
This record is also representative of lines 3 and 4 that were also generated; all of these lines exhibit a similar phenotype in combination with Tg(MMTVtTA)1Mam.
Bitransgenic mice with this transgene in combination with Tg(MMTVtTA)1Mam, when tetracycline administration is stopped, are models for B cell acute lymphoblastic leukemia (ALL); line 2 exhibits the greatest leukemia susceptibility (Figure 1). (J:72377)
|
| References |
|
Original: |
J:72377
Huettner CS et al.,
"Reversibility of acute B-cell leukaemia induced by BCR-ABL1."
Nat Genet 2000 Jan;24(1):57-60
|
|
All: |
13 reference(s)
|
|
Analysis Tools
